Treatment of stress fractures in athletes with intravenous pamidronate

Clinical Journal of Sport Medicine

Volumn 15, Issue 2, 2005, Pages 92-94

  Stewart, Gregory W ^a   Brunet, Michael E ^a   Manning, Melvin R ^a   Davis, Frederick A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bisphosphonates; Pamidronate; Stress fractures; Tibia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; ATHLETE; BONE MASS; CLINICAL ARTICLE; COLLEGE; COMPETITION; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MYALGIA; NAUSEA; NEUROPATHIC JOINT DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; STRESS FRACTURE; TRAINING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ATHLETIC INJURIES; DIPHOSPHONATES; FEMALE; FRACTURES, STRESS; HUMANS; NAUSEA; TREATMENT OUTCOME;

EID: 16244400798     PISSN: 1050642X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jsm.0000152716.06883.e0     Document Type: Article

References (11)

1. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging. 1999;15:285-296.
2. Guis S, Pellissier JF, Arniaud D, et al. Healing of Charcot's joint by pamidronate infusion. J Rheumatol. 1999;26:1843-1845.
3. Lipton A, Berenson JR. Bisphosphonate treatment of lytic bone metastases. Drugs Aging. 1999;14:241-246.
4. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17:846-854.
5. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999;21:389-406.
6. Zwas ST, Elkanovitch R, Frank G. Interpretation and classification of bone scintigraphic findings in stress fractures. J Nucl Med. 1987;28:452-457.
7. Flinn SD. Changes in stress fracture distribution and current treatment. Curr Sports Med Rep. 2002;1:272-277.
8. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;19:3434-3437.
9. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
10. Younes H, Farhat G, el Hajj FG. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom. 2002;5:143-149.
11. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97-106.